Objective |
To assess the efficacy and safety of gabapentin in patients with fibromyalgia. |
Methods |
A 12-week, randomized, double-blind study was designed to compare gabapentin (1,200-2,400 mg/day) (n = 75 patients) with placebo (n = 75 patients) for efficacy and safety in treating pain associated with fibromyalgia. The primary outcome measure was the Brief Pain Inventory (BPI) average pain severity score (range 0-10, where 0 = no pain and 10 = pain as bad as you can imagine). Response to treatment was defined as a reduction of 30% in this score. The primary analysis of efficacy for continuous variables was a longitudinal analysis of the intent-to-treat sample, with treatment-by-time interaction as the measure of effect. |
Results |
Gabapentin-treated patients displayed a significantly greater improvement in the BPI average pain severity score (P = 0.015; estimated difference between groups at week 12 = -0.92 [95% confidence interval -1.75, -0.71]). A significantly greater proportion of gabapentin-treated patients compared with placebo-treated patients achieved response at end point (51% versus 31%; P = 0.014). Gabapentin compared with placebo also significantly improved the BPI average pain interference score, the Fibromyalgia Impact Questionnaire total score, the Clinical Global Impression of Severity, the Patient Global Impression of Improvement, the Medical Outcomes Study (MOS) Sleep Problems Index, and the MOS Short Form 36 vitality score, but not the mean tender point pain threshold or the Montgomery Asberg Depression Rating Scale. Gabapentin was generally well tolerated. |
Conclusion |
Gabapentin (1,200-2,400 mg/day) is safe and efficacious for the treatment of pain and other symptoms associated with fibromyalgia. |
Los Angeles County Hospital
Monthly Paper Selection
Journal RSS (FEEDS):
By following the link below, you will be redirected to my Bloglines website. I set up a page with FEEDS from the main Rheumatology Journals, Internal Medicine Journals and Immunology Basic Science Journals:
http://www.bloglines.com/public/brunostoliver
In addition, I made available some FEEDS from Rheumatology Journals below, but be aware that this is not a complete list of each Journal issue. To get the complete list, click in the link above and you will be redirected to bloglines.com
Medscape Rheumatology Headlines
Physician's First Watch: Current Issue
Arthritis & Rheumatism
Annals of the Rheumatic Diseases current issue
Rheumatology - current issue
Current Opinion in Rheumatology - Current Table Of Contents
CER - Recent Issue
Arthritis Research & Therapy - Latest articles
JCR: Journal of Clinical Rheumatology - Current Table Of Contents
Nature Clinical Practice Rheumatology
Lupus current issue
Journal Links (Blogroll from Bloglines)
Rheumatology Journals Schedule
- Arthritis and Rheumatism: Monthly
- Annals of Rheumatic Disease (The EULAR Journal): Monthly
- Journal of Rheumatology: bi-weekly (only e-mail TOC/no RSS)
- Rheumatology (Oxford): Monthly
- Current Opinion in Rheumatology (COR): 6 issues/year (bi-monthly)
- Clinical and Experimental Rheumatology (CER): 6 issues/year (bi-monthly)
- Arthritis Research and Therapy: 6 issues/year (bi-monthly)
- Journal of Clinical Rheumatology: 6 issues/year (bi-monthly)
- Scandinavian Journal of Rheumatology: 6 issues/year (bi-monthly) !No issues since July 2006
- Rheumatic Disease Clinics of North America: (4-5 reviews/year): Receive e-mail TOC. No RSS.
- Seminars in Arthritis and Rheumatism: 6 issues/year (bi-monthly)+ 2 Supplements: Receive e-mail TOC. No RSS.
- Nature Clinical Practice Rheumatology: Monthly
- Lupus Journal: Monthly
Internal Medicine Journals Schedule
- Archives of Internal Medicine: Bi-weelky (Monday)
- Annals of Internal Medicine: No RSS available: Bi-weekly (Tuesday) (only e-mail TOC)
- JAMA: Weekly (Wednesday)
- NEJM: Weekly (Thursday)
- Lancet: Weekly (Friday)
- British Medical Journal: Weekly (Saturday)
Monday, April 9, 2007
Arthritis and Rheumatism (April 2007)
Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment